Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL).
À¶Ý®ÊÓƵ
Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL). Foss, F. M., Querfeld, C., Porcu, P., Kim, Y. H., Pacheco, T., Halwani, A., DeSimone, J., William, B. M., Seto, A. G., Ruckman, J., Landry, M. L., Jackson, A. L., Pestano, L. A., Dickinson, B. A., Sanseverino, M., Rodman, D. M., Rubin, P., Gordon, G., Marshall, W. S. AMER SOC CLINICAL ONCOLOGY. 2017View details for
View details for